Even Big Pharma can no longer deny the statin-diabetes link

No other drug could be linked to so many devastating diseases and conditions as statins are… and remain on the market.

None.

And if even just a sliver of those side effects were ever linked to a supplement, the National Guard would probably be called in to remove it from store shelves!

These “Teflon drugs,” however, have managed to not only remain on the market… but be prescribed to more and more unsuspecting patients every single day.

Now, a new study on statins — one done by a prominent doctor who has supported their use, no less — has again linked meds such as Lipitor, Zocor, and Crestor to type 2 diabetes.

This picture is as clear as day: If you take a statin, you’re running a very big risk of ending up diabetic.

The fast-track to insulin
The reams of research linking statins to diabetes is growing about as fast as Jack’s beanstalk!

These studies are coming from all corners of the globe, and they are all giving us the same results.

It doesn’t seem to matter if you’re a man or woman… middle-aged or a senior… not in great shape or fit as a fiddle… the link to new-onset type 2 diabetes keeps appearing.

In Finland, scientists researched close to 9,000 men who took the drugs over six years. They were found to have a nearly 50 percent higher risk of type 2.

For senior women in Australia, those odds were remarkably consistent — up to a 51 percent chance for developing diabetes.

And University of Texas researchers crunched the numbers on extremely healthy active-duty servicemen and women. That study not only revealed an astronomical 87 percent higher risk of diabetes… but also found that the risk of complications such as nerve damage, kidney failure and heart disease were off the charts as well.

Now, Dr. Jill Crandall, head of the Albert Einstein College of Medicine diabetes research center, has done (as if we needed it!) yet another study.

This one looked at several thousand people considered at a high risk for diabetes, and guess what she found? That’s right — taking a statin can be the final straw.

And in an interesting twist, Dr. Crandall’s study was financed by a truckload of statin enthusiasts, including the CDC, Bristol-Myers Squibb, and Merck — the last of which makes the statin drug Zocor.

As HSI panel member Dr. Allan Spreen said, “The drug companies must be freaking out!”

Maybe — but no more so than patients who find out they’re taking a drug that’s not only linked to diabetes, but severe muscle pain and weakness, extreme fatigue, brain fog, Parkinson’s disease, and hardening of the arteries.

Dr. Crandall tried her best to blunt the bad news she uncovered — an almost 40 percent increased risk of receiving a diabetes diagnosis — by emphatically saying patients should not stop taking the drugs. She claimed that the “mechanisms” by which these drugs cause type 2 are “poorly understood” and that all you need is to be “monitored” for diabetes “while on a statin.”

Well, thanks, Dr. Crandall, but I think we understand plenty!

And if you’re wondering about all those “benefits” statins are supposed to deliver, well, they’re about as real as a $3 bill.

Dr. John Mandrola, a specialist in heart rhythm disorders practicing in Kentucky, recently revealed that although prescribing a high-dose statin to a patient who has suffered a stroke is an untouchable policy in hospitals, there’s really no data to back it up.

The benefits found in the Pfizer-sponsored studies, he said, “barely met statistical significance.” And yet, you’d be hard pressed to find a cardiologist who doesn’t load up their stroke patients with enough statin pills to choke a horse.

And even for those not in the stroke club, the benefits are slim to none.

The bottom line here is that far too many physicians are practicing “cookbook” medicine — when your doctor follows his instruction manual to the letter rather than his own know-how!

If yours happens to be one of them, maybe it’s high time to find yourself another doctor.

“Statin use raises diabetes risk ‘even in high-risk patients’” Liam Davenport, October 23, 2017, Medscape, medscape.com